Triple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III)
https://doi.org/10.18087/cardio.2021.10.n1789
Abstract
The article presents a clinical case of successful triple combination therapy in a female patient with functional class III idiopathic pulmonary arterial hypertension. Supplementing the previous macitentan and riociguat treatment with selexipag reduced the severity of clinical manifestations of pulmonary hypertension. Also, the treatment efficacy was demonstrated by improvement of laboratory and instrumental indexes. Time-related changes were evaluated at 3 months after initiation of the selexipag treatment.
Keywords
Idiopathic pulmonary arterial hypertension,
triple combination therapy,
selexipag,
riociguat,
macitentan
Supporting agencies: No conflict of interest is reported.
About the Authors
A. A. Proshkina
Sechenov Moscow State Medical University, Moscow, Russia
Russian Federation
Russian Federation
student
N. A. Tsareva
Sechenov Moscow State Medical University, Moscow, Russia
Russian Federation
Russian Federation
pulmonologist, associate professor
G. V. Nekludova
Sechenov Moscow State Medical University, Moscow, Russia
Russian Federation
Russian Federation
pulmonologist, professor
S. N. Avdeev
Sechenov Moscow State Medical University, Moscow, Russia
Russian Federation
Russian Federation
pulmonologist, professor, head of department
References
1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801913. DOI: 10.1183/13993003.01913-2018
2. Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal. 2016;37(1):67–119. DOI: 10.1093/eurheartj/ehv317
3. Ministry of Health of Russian Federation. Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Av. at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_LG.pdf.
4. Chazova I.E., Martynyuk T.V., Valieva Z.S., Azizov V.A., Barbarash O.L., Veselova T.N. et al. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertension. Eurasian Cardiology Journal. 2020;1(30):78–122. DOI: 10.24411/2076-4766-2020-10002-1-78-122
5. Butrous G. Pulmonary hypertension: From an orphan disease to a global epidemic. Global Cardiology Science and Practice. 2020;2020(1):e202005. DOI: 10.21542/gcsp.2020.5
6. Swinnen K, Quarck R, Godinas L, Belge C, Delcroix M. Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. European Respiratory Review. 2019;28(154):190050. DOI: 10.1183/16000617.0050-2019
7. Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A et al. Diagnosis of pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801904. DOI: 10.1183/13993003.01904-2018
8. Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O et al. Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal. 2019;53(1):1801889. DOI: 10.1183/13993003.01889-2018
9. Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M et al. Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal. 2019;53(1):1801908. DOI: 10.1183/13993003.01908-2018
10. Parikh V, Bhardwaj A, Nair A. Pharmacotherapy for pulmonary arterial hypertension. Journal of Thoracic Disease. 2019;11(S14): S1767–81. DOI: 10.21037/jtd.2019.09.14
11. Nair A. Pharmacologic therapy for pulmonary artery hypertension. Current Opinion in Cardiology. 2020;35(6):643–56. DOI: 10.1097/HCO.0000000000000796
12. Coons JC, Pogue K, Kolodziej AR, Hirsch GA, George MP. Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update. Current Cardiology Reports. 2019;21(11):141. DOI: 10.1007/s11886-019-1235-4
13. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2015;373(26):2522–33. DOI: 10.1056/NEJMoa1503184
14. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlócai K, Galiè N et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. European Respiratory Journal. 2012;40(4):874–80. DOI: 10.1183/09031936.00137511
15. Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565–86. DOI: 10.1016/j.chest.2018.11.030
16. Chin KM, Sitbon O, Doelberg M, Gibbs JSSR, Hoeper MM, Martin N et al. Efficacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study. American Thoracic Society 2020 International Conference. Av. at: https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928. 2020. [DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2928]
17. Panagiotidou E, Boutou A, Pitsiou G. An evaluation of selexipag for the treatment of pulmonary hypertension. Expert Opinion on Pharmacotherapy. 2021;22(1):29–36. DOI: 10.1080/14656566.2020.1812579
18. Barnikel M, Kneidinger N, Klenner F, Waelde A, Arnold P, Sonneck T et al. Real-life data on Selexipag for the treatment of pulmonary hypertension. Pulmonary Circulation. 2019;9(1):204589401983219. DOI: 10.1177/2045894019832199
19. Narechania S, Torbic H, Tonelli AR. Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics. 2020;25(2):131–41. DOI: 10.1177/1074248419877409
20. Actelion. Effect of Selexipag on Daily Life Physical Activity of Patients with Pulmonary Arterial Hypertension. (TRACE). 2021. ClinicalTrials.gov Identifier: NCT03078907. Av. at: https://clinicaltrials.gov/ct2/show/NCT03078907.
Review
For citations:
Proshkina A.A., Tsareva N.A., Nekludova G.V., Avdeev S.N. Triple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III). Kardiologiia. 2021;61(10):104-107. (In Russ.) https://doi.org/10.18087/cardio.2021.10.n1789
Views:
963
Email this article 
Post a Comment 
